Search Results

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets.

Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced business highlights and financial results for the three months ended September 30, 2021.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant.

Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended June 30, 2021.

Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US subsidiaries dedicated to the legacy business and its Marietta, Georgia, manufacturing facility, to Alora Pharmaceuticals, LLC, effective August 27, 2021.

Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date: Thursday, November 18, 2021